Last updated on April 17, 2014 at 9:08 EDT

Health Robotics’ Announces Memorial Care’s [CA] 57% Savings From Ameridose’s Switch to i.v.STATION Robot

August 12, 2013

BOZEN, Sud-Tirol, Italy, August 12, 2013 /PRNewswire/ –

Health Robotics recently announced that Memorial Care Health System in Long Beach
released to Health Robotics’ User Group an ROI study focused on 57% average savings as a
result of insourcing Sterile Compounding patient doses on the i.v.STATION Robot, compared
to its prior equivalent costs with Ameridose.

Ed Wong,Director of Pharmacy at Memorial Care’s Miller Hospitalstated: “Just as an
example of the i.v.STATION Robot cost benefits at Memorial Care, for a single active
pharmaceutical principle [Oxytocin], we documented savings of $73,874 (or 60%) over a 21
month period between August 2011 and April 2013. i.v.STATION utilized standard
commercially-available Baxter Viaflex Bags and APP drug vials of 10ml and 30ml, with the
Robot preparing dilutions of 13,876 patient doses of 1 Liter Bags LR, and 3,955 patient
doses of 500ml IV Bags at 0.9% NS, at an internal cost of $49,954 compared to the prior
and equivalent Ameridose expense of $123,828.”

Under the current leadership of William Churchill from Brigham & Women’s Hospital and
Paul Bush from Duke University Medical Center, Health Robotics’ User Group holds
teleconferences once per quarter for its members, in addition to an annual meeting during
ASHP Midyear, which provides an ideal forum for progressive Health-System Pharmacies to
compare experiences, best practices, and cost savings, on how to improve Sterile
Compounding quality and lower costs.

Gaspar DeViedma, Health Robotics’ Executive Vice President stated: “I’m very proud
that i.v.STATION continues on its undeterred path to collect under-12 month ROIs and cost
justifications from both Academic and Community Health-Systems pharmacies in North
America, following prior similar published reports from Brigham & Women’s Hospital [MA],
LeeSar Compounding Services [FL], Allegiance Health [MI], Candler Hospital [GA], St.
Joseph Hospital [GA], and several others.

These documented benefits are especially important in the wake of the recent
legislative attempts in Massachusetts [ground zero for 2012 deadly contamination affecting
patients nationwide], http://www.jeffreysanchez.org/compounding-pharmacy-bill-report,
and the appalling results of FDA’s 2013 inspection reports at 50 sites:


About Health Robotics:

Founded in 2006 and now reaching 80% total IV Robots market share in the world
[including over 90% the Oncology Robots global market], Health Robotics is the undisputed
leading supplier of life-critical intravenous medication robots, providing almost 500
hospital installations in 5 continents with the only fully-integrated Robotics-based
technology, IV Workflow, and manual compounding software automation solutions. Health
Robotics’ second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have
been found [through scientific and peer-reviewed studies[1],[2],[3]] to greatly contribute
to ease hospitals’ growing pressures to improve patient safety[1], increase throughput,
and contain costs[1],[3]. Through the effective and efficient production of sterile,
accurate, tamper-evident and ready-to-administer IVs, Health Robotics’ medical devices and
integrated workflow solutions help hospitals eliminate life-threatening drug[1] and
diluent[1] exchange errors, improve drug potency[2], decrease other medical mistakes and
sterility risks, work more efficiently[1],[3], reduce waste and controlled substances’
diversion, reduce pharmacy technician upper-limb injuries[3], and diminish the gap between
rising patient volume/acuity and scarce nursing and pharmacy staff. For more information,
please visit: http://www.health-robotics.com


1. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger,
Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and
Rothschild. Brigham & Women’s Hospital, Massachusetts College of Pharmacy, and Harvard
Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

2. Validation of an automated method for compounding monoclonal antibody patient
doses: case studies of Avastin(R), Remicade(R), and Herceptin(R). Peters, Capelle,
Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

3. Comparing the upper limb disorder risks associated with manual and automated
cytotoxic compounding. McLeod, Zochowska, Leonard, Crow, Jacklin, Dean, Franklin. Imperial
College Healthcare NHS Trust. European Journal of Hospital Pharmacy April 2012.

        For additional information, please contact:
        Luisa Celeghin

SOURCE Health Robotics

Source: PR Newswire